Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CTT Pharmaceutical Holdings, Inc. (CTTH)
USD0.08
0.00 (-0.13%)
US OTC Healthcare Medical - Pharmaceuticals
Address
3853 Northdale Blvd 33624
Tampa, FL, US
Tampa, FL, US
CEO
Ryan Khouri
Website
cttpharmaceuticals.com
IPO
1997-04-18
CIK 1035422 ISIN US12651E1064
Description
CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment. It focuses on fast dissolving drug delivery systems. The company’s technology platform includes the development of advanced oral delivery thin wafers infused with both natural and/or synthetic cannabis extracts to deliver treatment as an alternate to smoking and ingestion. Its principal asset is a patented orally administered dissolvable strip. The company is based in Tampa, Florida.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.08
0.00 (-0.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
21.0K
Beta
0.71
Float Shares
18.50M
Free Float %
86.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -12.73% | -3.36% | -7.95% | +3.30% | +19.79% | +65.14% | +267.35% | +18.03% | +140.00% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.08
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-97.80
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%+30.8% ★ Q4'25: -1,200.0% (vs Q4'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%-216.3% Q4'25: -100.2% (vs Q4'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+9.9% Q4'25: +7.4% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.16× Q4'25: -0.36× (vs Q4'24)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.03M
OE per share TTM
-1.20
Owner's Yield
-24.57%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
229,943.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
278.2K
Shares disposed
—
Cash buys
4.00
Cash sales
—
Net activity
+278,200
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-17 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 8,300 | 0.06 | 456.50 | 7,845,956 | D | ↗ |
| 2025-11-20 | CTT PHARMACEUTICAL HOLDINGS, INC. | Director | P-Purchase | A | CTTH | 200,000 | 0.04 | 8.0K | 3,734,003 | D | ↗ |
| 2025-10-31 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 7,000 | 0.06 | 420.00 | 7,774,756 | D | ↗ |
| 2025-09-23 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 6,815 | 0.06 | 408.90 | 7,767,756 | D | ↗ |
| 2025-08-02 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 44,085 | 0.05 | 2.0K | 7,760,941 | D | ↗ |
| 2025-08-01 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | A-Award | A | CTTH | 750,000 | 0.04 | 30.0K | 7,716,856 | D | ↗ |
| 2025-07-08 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | Shares Acquired | 8,000 | 0.03 | 240.00 | 6,951,056 | D | ↗ |
| 2025-06-26 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | Shares Acquired | 39,600 | 0.03 | 990.00 | 6,943,056 | D | ↗ |
| 2025-06-23 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | Shares Acquired | 16,100 | 0.03 | 402.50 | 6,903,456 | D | ↗ |
| 2025-06-09 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 82,158 | 0.05 | 4.1K | 6,832,558 | D | ↗ |
| 2025-04-11 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | A-Award | A | CTTH | 150,000 | 0.06 | 9.0K | 6,750,400 | D | ↗ |
| 2025-04-09 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 9,984 | 0.07 | 648.96 | 6,600,400 | D | ↗ |
| 2025-03-31 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 15,510 | 0.05 | 775.50 | 6,590,416 | D | ↗ |
| 2025-03-11 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 5,400 | 0.06 | 324.00 | 6,574,906 | D | ↗ |
| 2025-03-07 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 11,950 | 0.09 | 1.1K | 6,569,506 | D | ↗ |
| 2025-02-05 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 5,200 | 0.12 | 624.00 | 6,557,556 | D | ↗ |
| 2024-11-25 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 23,346 | 0.06 | 1.4K | 5,818,846 | D | ↗ |
| 2024-06-13 | CTT PHARMACEUTICAL HOLDINGS, INC. | Officer | P-Purchase | A | CTTH | 54,798 | 0.03 | 1.4K | 6,887,356 | D | ↗ |
Executive team
Top executives
Shares Outstanding
21.35M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Marc Lakmaaker | Special Advisor & Senior Vice President of Commercial Development | — | male |
| Pankaj Modi | Founder & Consultant | — | — |
| Ryan Khouri | Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTTH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
